

**Kyrgyz Republic
VACCINE SUPPORT**

This Decision Letter sets out the Programme Terms of a Programme.

| | | | |
|---|----------------------------|-------------|--------------------|
| 1. Country: Kyrgyz Rep | | | |
| 2. Grant Number: 1115-KGZ-04a-X / 08-KGZ-08b-Y | | | |
| 3. Date of Decision Letter: 06/10/2014 | | | |
| 4. Date of the Partnership Framework Agreement: 16/05/2014 | | | |
| 5. Programme Title: NVS, Pentavalent Routine | | | |
| 6. Vaccine type: Pentavalent | | | |
| 7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID | | | |
| 8. Programme Duration¹: 2009 - 2015 | | | |
| 9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): | | | |
| | 2009-2014 | 2015 | Total ² |
| Programme Budget (US\$) | US\$6,995,638 ³ | US\$844,500 | US\$7,840,138 |
| 10. Vaccine Introduction Grant: US\$ 100,000 already disbursed in 2009. | | | |

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴

| Type of supplies to be purchased with GAVI funds in each year | 2009-2014 | 2015 |
|---|----------------------------|-------------|
| Number of Pentavalent vaccines doses | | 407,000 |
| Number of AD syringes | | 472,900 |
| Number of re-constitution syringes | | |
| Number of safety boxes | | 5,225 |
| Annual Amounts (US\$) | US\$6,995,638 ⁵ | US\$844,500 |

12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.

13. Self-procurement: Not applicable.

14. Co-financing obligations: Reference code: 1115-KGZ-04a-X-C According to the Co-Financing Policy, the Country falls within the group Low Income.

The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year. However the table below is based on the Country's current co-financing grouping as a low income country and the co-financing amounts for 2016 onwards will be revised following the High Level Review Panel in 2015 as the country moves into intermediate country category starting from January 2015.

| Type of supplies to be purchased with Country funds in each year | 2015 |
|--|------------|
| Number of vaccine doses | 45,100 |
| Number of AD syringes | |
| Number of re-constitution syringes | |
| Number of safety boxes | |
| Value of vaccine doses (US\$) | US\$87,710 |
| Total Co-Financing Payments (US\$) (including freight) | US\$90,500 |

15. Operational support for campaigns: Not applicable

⁴ This is the amount that GAVI has approved.

⁵ This is the consolidated amount for all previously approved years.

| 16. Additional documents to be delivered for future disbursements: | |
|--|-----------|
| Reports, documents and other deliverables | Due dates |
| Annual Progress Report as instructed by the Gavi Secretariat | 2015 |
| Along with Annual Progress report the country is requested to submit a new cMYP for renewal of Pentavalent vaccine support | 2015 |

17. Financial Clarifications: Country to revise the following as explained in the Internal Appraisal report (see the attached report in the email):

For ISS account: Please revise application of exchange rates in APR for expenditure and closing balance to reflect consistency between FS and APR. Currently the expenditure in APR is US\$ 212,088, in FS – US\$ 236,139. The closing balance in APR is US\$ 368,487 and in FS – US\$ 333,029. At the end of year rate of 1 USD = 54 SOM, the ending balance of SOM 16,151,915 should equal approximately US\$ 299,110.

18. Other conditions: N/A

Signed by,
On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes
6 October 2014

